Diabetes & CVD: Time for a multifactorial approach

10' education - Dec. 6, 2018 - WCC Dubai, UAE - John E Deanfield, MD - University College London, United Kingdom - Online CME

Prof. Deanfield sheds light on the relation between T2DM and CVD, and how studies evaluating novel classes of antidiabetic drugs have evolved over time, from revealing safety signals to demonstrating CV benefit.

Video navigation menu

Diabetes patients have a high CV risk 00:30
New treatment goals in diabetes to reduce CV complications 02:36
Major CV benefits with 2 new classes of drugs 05:00
New drugs:: trial data and unanswered questions 08:43
How can diabetes with associated CVD be prevented? 10:56
Conclusion: new era for treatment of diabetes & CVD 16:42

Educational information

This lecture by prof. John E Deanfield was part of a CME-accredited symposium "Diabetes, Cardiology & Novel Therapeutic Approaches" held during WCC 2018 in Dubai.

Faculty

Prof. John E. Deanfield, MD - Professor of Cardiology - Director, National Centre for Cardiovascular Prevention and Outcomes, University College London, United Kingdom

Disclosures

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk.

Online-CME

This is available as accredited online CME for members. Click the button below to enroll:

Enroll

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.